Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL11417227 | 0.98 | ALDH1A1 (0.61) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL30894712 | 0.98 | ALDH1A1 (0.67) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL30894713 | 0.98 | ALDH1A1 (0.67) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL1302034 | 0.98 | ALDH1A1 (0.67) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL36441 | 0.98 | ALDH1A1 (0.67) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL4599271 | 0.90 | ALDH1A1 (0.56) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL11701993 | 0.90 | ALDH1A1 (0.56) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL1398185 | 0.90 | ALDH1A1 (0.56) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL28052464 | 0.88 | ALDH1A1 (0.74) | ALDH1A1ALOX15CA12CA1CA2 | |
| Phthalic Acid SCHEMBL22074773 | 0.88 | ALDH1A1 (0.74) | ALDH1A1ALOX15CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613333-A1 | ORAL EXTENDED RELEASE COMPRESSED TABLETS OF MULTIPARTICULATES | Pharmacia Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1610764-A1 | TASTE-MASKING VEHICLE FOR COATED OXAZOLIDINONE PARTICLES | Pharmacia Corporation (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1592400-A2 | SUSPENSION VEHICLE FOR COATED DRUG PARTICLES | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040228915-A1 | Oral extended release compressed tablets of multiparticulates | NOACK ROBERT M (US) | 2004-11-18 | — | — | US | disclosed |
| WO-2004087175-A1 | ORAL EXTENDED RELEASE COMPRESSED TABLETS OF MULTIPARTICULATES | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087108-A1 | TASTE-MASKING VEHICLE FOR COATED OXAZOLIDINONE PARTICLES | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040191326-A1 | Taste-masking vehicle for coated oxazolidinone particles | REO JOSEPH P (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040170686-A1 | Suspension vehicle for coated drug particles | FREDRICKSON JENNIFER K (US) | 2004-09-02 | — | — | US | disclosed |
| WO-2004066911-A2 | SUSPENSION VEHICLE FOR COATED DRUG PARTICLES | PHARMACIA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191326-A1 | Taste-masking vehicle for coated oxazolidinone particles | SORD, OXA1L, TAS2R20 | ESR1 4600/4885ALDH1A1 2141/4885ALOX15 2139/4885 |
| US-20040170686-A1 | Suspension vehicle for coated drug particles | TAS2R5, TAS2R41, TAS2R60 | ESR1 4706/4885ALDH1A1 817/4885ALOX15 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.